CN-121537499-B - Bionic peptide derived from human beta defensin-3 as well as preparation method and application thereof

Abstract

The invention discloses a bionic peptide derived from human beta defensin-3, and a preparation method and application thereof. The amino acid sequence of the bionic peptide comprises a sequence shown as SEQ ID NO. 1. According to the invention, the key hydrogen bonding residues and the active structural domains are determined through butt joint calculation of hBD-3 and EGFR/CD36 receptors, and the receptor recognition function is reserved through sequence connection and structure optimization. The bionic peptide designed by the invention has bioactivity, structural controllability and material compatibility, and can be widely applied to the fields of epithelial tissue repair, anti-fibrosis regulation and control and biomedical material functionalization.

Inventors

• CHEN YANYAN
• LI LONGWEI
• DAI JIANWU

Assignees

• 中国科学院苏州纳米技术与纳米仿生研究所

Dates

Publication Date

20260508

Application Date

20260122

Claims (5)

1. 1. A bionic peptide derived from human beta defensin-3 is characterized in that the amino acid sequence of the bionic peptide is shown as SEQ ID NO. 1.
2. 2. A bionic peptide derived from human beta defensin-3 is characterized in that the amino acid sequence of the bionic peptide is shown as SEQ ID NO. 4.
3. 3. Use of a biomimetic peptide according to claim 1 or 2 for the manufacture of a medicament for skin healing.
4. 4. Use of the biomimetic peptide according to claim 1 or 2 for the preparation of a biomaterial for skin healing.
5. 5. A method for preparing a collagen matrix material, comprising immobilizing the biomimetic peptide according to claim 1 or 2 on the surface of a decellularized matrix or a collagen scaffold via a collagen binding domain.

Description

Bionic peptide derived from human beta defensin-3 as well as preparation method and application thereof Technical Field The invention belongs to the technical field of molecular docking and biomedical materials, relates to a bionic peptide derived from human beta defensin-3, and a preparation method and application thereof, and in particular relates to a human beta defensin-3 (hBD-3) bionic functional peptide based on molecular docking and dynamics simulation design and application thereof in promoting regeneration of epithelial tissues, regulating and controlling fibroblast phenotype and inhibiting tissue fibrosis. Background Tissue repair is a complex biological process involving multiple stages, multiple cells, where epithelial regeneration and matrix remodeling are key elements in determining tissue morphology and functional recovery. In physiological repair environments, fibroblasts are involved in matrix synthesis and remodeling by temporary activation, but in chronic inflammatory, infectious or overstrain reactions, fibroblasts often transform into a continuously activated fibroblast or inflammatory phenotype, accompanied by excessive collagen deposition and extracellular matrix disorders, leading to tissue scarring and repair failure. The pathological repair process not only affects the structural integrity of tissues, but also obviously reduces the function regeneration efficiency, and becomes one of the core problems to be solved in the fields of tissue engineering and regenerative medicine. Human beta Defensin-3 (hBD-3) is an endogenous polypeptide with broad-spectrum antibacterial activity and immune regulation and tissue repair potential. The hBD-3 molecule contains three pairs of complex disulfide structures and high-density cationic amino acid residues, which not only results in high chemical synthesis cost and poor conformational stability, but also easily loses conformation-dependent bioactivity in the immobilization process of biomedical materials. Therefore, its transformation application in the field of tissue engineering is significantly limited. To overcome the above limitations, researchers have recently begun to try biomimetic engineering strategies based on natural antimicrobial peptides to obtain short peptide molecules with similar biological functions but higher stability and modifiable properties by screening for active fragments, sequence optimization or structural simplification. However, current engineering relies on empirical truncations and lack of systematic receptor binding site analysis and structural validation, resulting in unstable biological activity or ambiguous mechanisms of action of the resulting peptide fragments. Therefore, it is highly desirable to provide a biomimetic peptide that combines bioactivity, structural controllability and material compatibility. Disclosure of Invention Aiming at the defects and the actual demands of the prior art, the invention provides a bionic peptide derived from human beta defensin-3, a preparation method and application thereof, the bionic peptide designed by the invention has bioactivity, structural controllability and material compatibility, and can be widely applied to the fields of epithelial tissue repair, anti-fibrosis regulation and control and biomedical material functionalization. In order to achieve the aim of the invention, the invention adopts the following technical scheme: in a first aspect, the invention provides a biomimetic peptide derived from human beta defensin-3, the amino acid sequence of the biomimetic peptide comprising the sequence as shown in SEQ ID NO. 1. In the invention, the key hydrogen bonding residue and the active structural domain are determined through butt joint calculation of hBD-3 and EGFR/CD36 receptor, and the receptor recognition function is reserved through sequence connection and structure optimization. SEQ ID NO.1:YYCRVRGGRSGGRKCSRRKK。 Preferably, the biomimetic peptide further comprises a collagen binding domain. Preferably, the amino acid sequence of the collagen binding domain comprises the sequence shown as SEQ ID NO. 2. SEQ ID NO.2:TKKTLRT。 Preferably, the biomimetic peptide further comprises a linker peptide, the amino acid sequence of which comprises any one of the following: (1) A flexible linker peptide consisting of glycine and serine; (2) The sequence is Wherein n is 1, 2, 3 or 4; (3) The sequence is Wherein n is 1, 2, 3, 4 or 5; (4) The sequence is Wherein n is 1, 2, 3, 4 or 5; (5) A linker peptide consisting of a fragment, variant or combination of any one of (1) - (4). Preferably, the amino acid sequence of the connecting peptide comprises a sequence as shown in SEQ ID NO. 3. SEQ ID NO.3:GGGGS。 Preferably, the amino acid sequence of the biomimetic peptide comprises a sequence as shown in SEQ ID NO. 4. SEQ ID NO.4:TKKTLRTGGGGSYYCRVRGGRSGGRKCSRRKK。 It is understood that the bionic peptide described in the present invention includes any bionic peptide with a connecting pep